Woodford on sciences business conversion chasm
In his second piece from the Woodford Investment Roadshows, Gary Corcoran looks at Woodford’s views on AstraZeneca, research and Britain’s track record of converting great science into great business.
AstraZeneca
-
-
Pa analysis valuing astra zeneca without woodford
The battle for AstraZeneca between Pfizer, the UK government and the existing shareholders of both companies is, as far as investors are concerned, all about its valuation - nothing more, nothing less.
-
AstraZeneca shares up 16 despite Pfizer knockback
US drug giant tries again